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Summary The incidence of subsequent primary cancers was assessed in relation to treatment for a cohort of
7,203 patients from the Birmingham and West Midlands Cancer Registry diagnosed between 1957 and 1976.
The total of 213 cancers observed one or more years after treatment for ovarian cancer (mean follow-up=6.5
person-years) represented a significant excess (observed (0)=213, expected (E)= 140.07, relative risk
(RR) = 1.5, 95% CI 1.3-1.7, P.<0.001). Among patients whose treatment included chemotherapy (CT), with
or without radiotherapy (RT), the risk of acute and non-lymphocytic leukaemia (A+NLL) was significantly
increased (O=5, E=0.18, RR=27.8, 95% CI 9.0-64.8, P<0.001). The relative risks ofA+NLL following RT
without CT (RR=4.5) and after other treatments (RR=2.9) were not significantly in excess of 1.0.
Significant excesses of subsequent cancers were observed at several sites: breast (RR= 1.7, 95% CI 1.3-2.2),
lung (RR=2.0, 95% CI 1.3-3.4), colon and rectum (RR= 1.6, 95% CI 1.1-2.3), urinary system (RR= 1.9,
95% CI 0.9-3.7), nervous system (RR=3.3, 95% CI 1.2-7.3) and connective tissue (RR=6.7, 95% CI 1.8-
17.1) but the relationship with type of treatment was not so clearly defined as that for leukaemia. Although
the treatment groups were broad and based on routinely collected data, they can enhance the use of cohort
analyses for exploratory and monitoring purposes.
The overall survival of patients with ovarian cancer is very
poor, because many present with late-stage disease. How-
ever, those treated radically for less extensive disease may
survive for long periods and be at risk of subsequent
primary cancer. Among other factors, the type of treatment
used might affect this subsequent risk: removal of the
ovaries, especially in younger women, might reduce the later
risk of breast cancer; pelvic irradiation might increase the
risk of leukaemia and of some solid tumours, such as those
found for cervical cancer patients (Day & Boice, 1983);
intensive chemotherapy has also been linked with an
increased risk of leukaemia in many clinical studies. Cyto-
toxic alkylating agents are potential leukaemogens but
whether they will prove to be generally carcinogenic for sites
of solid cancers has still to be resolved.
Surgical treatment for ovarian cancer involves the removal
of at least one ovary. Frequently both ovaries and the uterus
are resected, thus removing these organs from further risk
and also modifying hormonal influences. External pelvic
irradiation has been used in the past to treat ovarian cancer.
Chemotherapy, usually by single agent drug, came into more
frequent use in the mid-1960s with melphalan, thiotepa,
chlorambucil and cyclophosphamide being the drugs most
commonly used in the earlier years. Leukaemia following
ovarian cancer was linked to chemotherapy (Reimer et al.,
1978) and a review of five clinical trials also showed a high
relative risk of acute and non-lymphocytic leukaemia in
patients treated by alkylating agents but not radiotherapy
(Greene et al., 1982). A cohort analysis of ovarian cancer
patients based on international registry data demonstrated
an increased risk of leukaemia and of certain other sites of
solid tumours which, in the absence of specific therapy data,
were suggestive of possible treatment effects (Kaldor et al.,
1987).
Although cytotoxic drugs and radiation may act as prim-
ary carcinogens both may have an indirect effect of increas-
ing cancer risk by immunodepression. Immunodepressant
therapy has been linked with the development of non-
Hodgkin's lymphoma and skin cancer (Kinlen et al., 1979).
The present study was undertaken (i) to assess the inci-
dence of subsequent primary cancers in a series of patients
with ovarian cancer drawn from the population-based data
of the Birmingham and West Midlands Cancer Registry, and
(ii) to ascertain whether any increased risks could be attribu-
table to treatment in this context. The overall results from
this series were included in a collaborative registry study
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(Kaldor et al., 1987) but the data have been re-analysed by
treatment group for this present report.
Materials and methods
Study population
The series included all patient registered with cancer of the
ovary or fallopian tube (International Classification of Dis-
eases, 8th Revision (ICD8) - rubric 183) between 1957 and
1976. A total of 7,203 patients were followed to death or to
31 December 1982, among whom 61 cases were lost to active
follow-up (0.8%), 11 having left the country.
Treatment
Four categories of treatment were considered: (1) RT,
radiotherapy only; (2) CT, chemotherapy only; (3) RT+CT,
radiotherapy and chemotherapy, either concurrent or at
intervals; (4) OT, other, i.e. not treated, surgery only,
surgery and hormone, hormone only. Patients in groups 1-3
may also have been treated surgically with or without
hormones. Where appropriate, groups 1 and 3 have been
combined as 'any RT' and groups 2 and 3 as 'any CT'.
Statistical methods
Subsequent cancers were identified from routine flagging of
registry data, scrutiny of case-notes at active follow-up and
from the multiple primary index. Equivocal cases were
routinely reviewed by a consultant to the Registry for a final
decision. Information held in the Registry on such cases was
reviewed to ensure their eligibility for the study.
All cancers observed either coincidentially or within the
first year of follow-up were excluded from the analysis
together with the expected numbers for the first year to
avoid possible bias in the ascertainment of early subsequent
cancers. Patients with coincidental cancers or cancers pre-
vious to the ovarian tumour were not, however, excluded
from the series. Patients developing a second primary cancer
also remained in the patient-years at risk after that event.
Analyses were carried out in terms of interval from diagnosis
of the index primary (ovary), age at diagnosis and treatment
group.
The observed numbers of second cancers at 38 different
sites were compared with the numbers that might have been
expected on the basis of regional cancer incidence rates,
applied to the person-years of follow-up for each age-group
and time-period. Evidence from numerous studies suggests
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that exposure to radiation or chemotherapeutic drugs gives
rise to acute leukaemia and other leukaemias of the myeloid
series. For this reason and to enable comparison with other
studies, the leukaemia rates were divided into two groups
(incidence rates for groups were derived by addition): (i) all
acute and non-lymphocytic leukaemia (A +NLL) (ICD8
204.0, 205, 206, 207.0, 207.2); (ii) chronic lymphatic and
leukaemia not otherwise specified (other) (ICD8 all other
204-207). A modified version of the PYRS program
(Coleman et al., 1986) was used for computation.
Relative risks (RR) were estimated as observed/expected
numbers. The level of significance of the deviation of this
from 1.0 was obtained by assuming that the observed
numbers follow a Poisson distribution. Exact one-tail
Poisson probabilities were computed or the Normal approxi-
mation was assumed where relevant and 95% confidence
intervals (CI) were computed using Byar's approximation
(Rothman & Boice, 1979). Differences between RRs were
tested by x2 analyses.
Excess morbidity rates (EMR) were computed as: (ob-
served-expected number)/person years at risk (PYR) x 103.
Treatment groups were compared and life-table estimates of
risk were obtained by log-rank procedures (Peto et al., 1977).
Results
The 3,300 patients (46.2%) who survived one or more years,
of a total series of 7,203, developed 213 subsequent primary
cancers during 21,446 person-years at risk (PYR) over a
follow-up period of 7-26 years. A total of 288 cancers had
been diagnosed previously or at the same time as the ovarian
cancer and 22 occurred within the first year of follow-up.
The distribution of the series by age, interval and treatment
groups in shown in Table I.
Treatment groups
Among the 3,300 first year survivors, 1,030 patients (31%)
were treated by RT, of whom 98.3% were also treated
surgically and 9.0% with hormones: 627 patients (19%)
received CT (surgery=94.4%, hormone= 17.5%); 414
(12.5%) received both RT and CT (surgery=97.8%, hor-
mone=30.9%); of the 1,229 patients in the OT group 95.3%
were treated surgically and 2.8% had received hormones.
Cancer morbidity
Main anatomical systems The distribution of the 213 subse-
quent cancers is shown in Table II. The 50% excess over the
expected number was highly significant (95% CI 1.3-1.7,
P<0.001). Sites at highest risk included breast and the
haematopoietic system, followed by respiratory system and,
to a lesser extent, colon, rectum and urinary system. The
small excess in the remainder could be attributed to cancers
of the nervous system and connective tissue, leaving 7
observed and 7.8 expected for all other sites.
Treatment groups In relation to treatment, the observed
excesses were highly significant in both the CT and OT
groups and of marginal significance in the RT group (Table
III). Although, overall, no difference between the groups
could be distinguished (x2 for heterogeneity (d.f. =3) = 5.92),
when the two groups receiving CT were combined (O=41,
E =20.04) and compared with RT+OT (O = 172, E = 120.04),
the relative risk for the combined chemotherapy groups was
significantly higher than for the rest (X2=3.90, P<0.05).
Within systems showing increased risks in Table IV,
individual sites were considered in relation to treatment.
Observed excesses reaching statistical significance were found
mainly on the OT group but, in general, the relative risks for
these same sites were raised across all treatment groups. The
notable exceptions were the excess of leukaemia in the RT
and CT groups and cancers of the nervous system in the RT
group.
Leukaemia A total of 11 leukaemias was diagnosed in the
series of which two were chronic lymphatic leukaemias, both
occurring in the RT group 4 and 17 years after treatment.
The excess of A+NLL (0=9, RR=7.0, P<0.001) was
highly significant and the risk was confined almost entirely
to the CT group (0=5, RR=43.5, P<0.001). No case,
however, occurred in those patients receiving combined
treatment (RT+CT) and although the risk was increased in
both the RT and OT, individually these excesses did not
achieve statistical significance.
The relative risk of A+NLL decreased over age at first
treatment, whereas EMRs were consistent with a constant
risk over age. The risk of A+NLL was highest at 1-4 years
after first treatment and was still elevated 10 or more years
later.
Table I Ovarian cancer: distribution of the series by age, interval and treatment group I +
years after diagnosis
Age at Ist primary diagnosis (years)
0-44 45-59 60+ Total
Treatment Interval
group (years) N1 PYR Ni PYR Ni PYR Ni PYR
RT 1-9 223 1,404 551 2,797 256 1,157 1,030 5,358
(No = 1,460) 10-19 113 792 211 1,167 70 340 394 2,299
20+ 43 130 48 134 9 19 100 283
Total 223 2,326 551 4,098 256 1,516 1,030 7,940
CT 1-9 92 358 293 849 242 567 627 1,774
(No= 1,523) 10-19 15 66 36 121 15 44 66 231
20+ 1 0 0 0 0 0 0 0
Total 92 424 293 970 242 611 627 2,005
RT+CT 1-9 73 235 224 599 117 258 414 1,092
(No=609) 10-19 11 31 19 75 7 19 37 125
20+ 0 0 0 0 0 0 0 0
Total 73 266 224 674 117 277 414 1,217
OT 1-9 272 1,973 439 2,660 518 2,378 1,229 7,011
(No=3,611) 10-19 174 1,108 216 1,266 142 611 532 2,985
20+ 51 114 57 139 12 35 120 288
Total 272 3,195 439 4,065 518 3,024 1,229 10,284
Total 660 6,211 1,507 9,807 1,133 5,428 3,300 21,446
(No =7,203)
No, number of patients entering study; N1, number of patients entering the interval.SUBSEQUENT PRIMARY CANCERS 455
Table II Ovarian cancer: subsequent primary cancers by anato-
mical system (3,300 patients, 1 + years follow-up)
Site ICD 8 0 E OIE 95% CI
All sites 140-208 213 140.07 1.5c 1.3-1.7
Mouth and pharynx 140-148 3 2.05 1.5 0.3-4.3
Upper digestive tract 150-152 12 12.40 1.0 0.5-1.7
Lower digestive tract 153-154 31 19.90 1.6a 1.1-2.2
Liver, gall-bladder and 155-157 6 5.85 1.0 0.4-2.2
pancreas
Respiratory system 160-162 18 9.21 2.0b 1.2-3.1
Skin 172-173 17 15.23 1.1 0.7-1.8
Breast 174 55 33.10 1.7c 1.3-2.2
Reproductive system 180-184 30 21.85 1.4 0.9-2.0
Urinary system 188-189 9 4.65 1.9a 0.9-3.7
Lymphatic system 200-203 4 3.12 1.3 0.3-3.3
Haematopoietic system 204-208 11 2.57 4.3c 2.1-7.7
Remainder 17 10.15 1.7a 1.0-2.7
0, observed number; E, expected number; CI, confidence interval.
ap<05; bp<0.01; cp<0.0f1.
Table III Ovarian cancer: subsequent primary
cancers at all sites by treatment group
Treatment
group 0 E OE 95% Cl
RT 65 49.44 1.3' 1.0-1.7
CT 29 12.95 2.2b 1.5-3.2
RT+CT 12 7.09 1.7 0.9-3.0
OT 107 70.60 1.5b 1.2-1.8
ap<o O5; bp<0.00l.
When patients receiving any CT were considered, a 28-fold
risk of A+NLL was found (Table V), the relative risk
remaining high over the three time-periods and decreasing
with age at ovarian cancer diagnosis. The overall EMR was
1.5/103 PYR and no obvious trend over age or time was
discernible.
The cumulative risk of A+NLL for patients receiving any
CT was 3.1% (1.9-4.4) at 10 years compared with 0.2% (0-
0.6) in the RT+OT group. A further leukaemia occurred at
22 years in the OT group, giving an overall risk of 1.1% (0-
2.2). Log-rank analysis showed a significant difference
between treatments (X2=9.22, P=0.01). The effect was
enhanced on correcting for age (X2=9.49, P<0.01). The risk
for any CT was 5.8-fold relative to that for the RT+OT
group. No significant difference in cumulative risk for
leukaemia between the three age groups could be shown
(x2=0.20), after correction for treatment 2=0.25.
Breast In relation to the risk of subsequent breast cancer,
the effects of ablating the ovaries might conflict with those
of incidental irradiation to the breast. A moderate increase
in risk was found in each treatment group, reaching signifi-
cance in the OT group only (Table IV). When the results for
any RT or CT were combined, the relative risk of subse-
quent breast cancer was 1.6 and was not significantly
different from the risk in the OT group (Table VI). How-
ever, in the pre-menopausal group (ages 0-44 years), the
relative risk was less than 1.0 in the RT/CT treated patients
compared with a two-fold risk among those treated by
surgery only. Nevertheless, only two out of seven observed
cases in this latter group retained an intact ovary. In the two
older age-groups both the proportion of observed cases
undergoing oophorectomy and the relative risk of breast
cancer was similar in each treatment group suggesting that,
in post-menopausal patients, ablation of the ovaries does not
alter appreciably the risk of breast cancer. The numbers in
the pre-menopausal group are too small to demonstrate a
significant ablatory effect.
No difference in the cumulative risk of breast cancer was
found between three treatment groups: RT, any CT and OT
(2=1.37, corrected for age). The risk relative to RT=1.0
was 1.3 for CT and 1.4 for OT, but the trend was not
significant (x2 = 1.13). On correcting for treatment-group, the
expected effect of increased cumulative risk of breast cancer
with increasing age at first treatment did not achieve the 5%
significance level (X2=3.73). These results suggest that the
increased relative risks in the younger age-groups incur an
absolute risk approaching that in older women.
Other sites Although the excess of cancers in the urinary
system was of marginal significance overall (Table IV), there
was no clear indication of a treatment effect. The relative
risk was 2.2 (O=5, E =2.24) in the RT/CT groups combined
and 1.7 (0=4, E=2.41) in the OT group. There was a
significant excess for 10 + years of follow-up (Table VII) but
risk was increased only in the OT group.
In the combined RT/CT groups the risk of connective
tissue cancers was increased 1-9 years after the ovarian
cancer (Table VII) and an excess of marginal significance
was also found for cancers of the nervous system in patients
receiving any RT in these earlier years of follow-up but a
moderate increase in all patients and in both time-periods
was observed. The relative risk of lung cancer for 10+ years
of follow-up was significantly higher than for 1-9 years
(x=4.8, P<0.05) but, again, the increase was not specifi-
cally related to the radiotherapy (Table VII). The risk of
colo-rectal cancers was significantly increased in the OT
group 1-9 years after treatment of the ovarian cancer, and
the relative risk was significantly higher in this group than in
the combined RT/CT groups. No excess was found at 10+
years.
Pelvic irradiation will deliver a relatively high dose to the
small intestine, colon, rectum, bladder, bone (- 2,000-
6,000 rad), kidney and connective tissue (- 200-700 rad). The
combined result for these sites in the RT group showed no
additional risk 10 or more years after treatment: 1-9 years
0=7, E=4.9, RR=1.4; 10+ years 0=4, E=3.3, RR= 1.2.
Although genital sites within the pelvic beam might also
be at high risk, surgical removal of the uterus and/or ovaries
has not been allowed for in the expected numbers. The
Table IV Ovarian cancer: subsequent primary cancers of specific sites by treatment group
RT CT RT+CT OT
Site
All sites
Colon
Rectum
Lung
Con. tiss.
Breast
Corpus
Bladder
Kidney
Nerv. sys.
Leukaemia
ICD8 0 E O/E O E E O/E E O/E
153
154
162
171
174
182
188
189
191-2
204-7
65
6
0
5
1
17
5
2
1
4
4
49.4
4.2
2.5
3.1
0.2
12.2
2.4
1.1
0.5
0.7
0.7
1.3a
1.4
1.6
5.0
1.4
2.1
1.8
2.0
5.7b
5.7b
29
2
3
6
2
1
0
0
5
12.9
1.1
0.7
0.8
0.1
3.1
0.6
0.3
0.1
0.2
0.2
2.2c 12
0.9 0
2.9 2
3.8a 1
10.0 0
1.9 4
3.3 1
3.3 1
- 0
- 0
25.Oc 0
7.1
0.6
0.3
0.5
0.0
1.8
0.4
0.2
0.1
0.1
0.1
1.7 107
- 12
6.7a 8
2.0 9
- 2
2.2 28
2.5 7
5.0 3
-
- 2
- 2
70.6 1.5c
6.7 1.8a
3.9 2.1
4.1 2.2a
0.3 6.7a
16.1 1.7
3.0 2.3a
1.7 1.8
0.7 1.4
0.8 2.5
1.1 1.8
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Table V Ovarian cancer: subsequent leukaemia by cell type, treatment and age at first
primary
0 E OIE (95% CI) EMR* (95% CI)
(A) by cell type
A+NLL 9 1.29 7.0c (3.2-13.2) 0.4 (0.2-0.7)
Other 2 0.81 2.5 (0.3-8.9) 0.1 (0-0.3)
Total 11 2.11 s.2c (2.6-9.3) 0.4 0.2-0.8)
(B) A+NLL by treatment
group
RT 2 0.44 4.5 (0.5-16.4) 0.2 (0-0.8)
CT 5 0.12 43.5c (13.4-97.2) 2.4 (0.8-5.7)
RT+CT 0 0.06 - -
OT 2 0.68 2.9 (0.3-10.6) 0.1 (0-0.6)
(C) A+NLL by age group
0-44 years 2 0.16 12.4a (1.4-45.1) 0.3 (0.1-1.1)
45-59 years 4 0.51 7.9b (2.1-20.1) 0.4 (0.1-1.0)
60+ years 3 0.63 4.8a (1.0-13.9) 0.4 (0.1-1.4)
(D) A+NLL by interval
from treatment
1-4 years 5 0.46 10.9c (3.5-25.4) 0.5 (0.4-3.0)
5-9 years 1 0.39 2.6 (0.1-14.3) 0.1 (0.1-2.1)
10+ years 3 0.45 6.7a (1.3-19.5) 0.4 (0.2-3.2)
(E) A+NLL following
any CT
(i) By interval
1-4 years 2 0.10 200.b (2.3-72.2) 1.0 (0.1-3.7)
5-9 years 1 0.05 20.0a (0.3-111.3) 1.0 (0.0-5.8)
10+ years 2 0.02 100.oc (11.2-361.1) 5.5 (0.6-20.1)
Total 5 0.18 27.8c (9.0-64.8) 1.5 (0.5-3.5)
(ii) By age
0-44 years 1 0.02 50.Oa (0.7-278.2) 1.4 (0.0-8.0)
45-59 years 2 0.07 28.6b (3.2-103.2) 1.2 (0.1-4.3)
60+ years 2 0.09 16.0b (2.5-80.2) 2.1 (0.2-8.0)
*EMR, excess morbidity rate (per 103 PYR); aP<0.05; bp<0.01; Cp<O.OO1.
Table VI Ovarian cancer: subsequent cancers of the breast in relation
to age at first primary and treatment groups
Treatment
RT/CT OT Total
Age group
(years) 0 E OIE 0 E O/E 0 E O/E
0-44 2 3.2 0.6 7 3.0 2.3a 9 6.2 1.5
(0) (2) (2)
45-59 17 9.2 1.8a 12 6.8 1.8a 29 16.0 1.8b
(6) (4) (10)
60+ 8 4.7 1.7 9 6.3 1.4 17 11.0 1.5
(3) (3) (6)
Total 27 17.1 1.6a 28 16.1 1.7b 55 33.2 1.7c
(9) (9) (18)
Numbers in parentheses are those with at least one ovary intact; ap<o05; bp<001.; cp<0.01.
relative risks for corpus uteri were 2.1, 2.2, 2.8 and 2.0 for
RT, CT, RT+CT and OT respectively. These results suggest
that the risk is similar in each treatment group and that the
real risk would have been substantially higher if surgical
intervention had been accounted for.
Discussion
Although the mortality rate was high in the series as a
whole, 3,300 patients survived at least one year to be at risk
for subsequent primary cancers. The large number of pre-
vious and coincidental primaries, together with the 1.5-fold
risk of subsequent cancers, reflect the broad spectrum of
associations between cancers of the ovary and other sites.
Such relationships were demonstrated in the early multiple
primary studies (Schottenfeld & Berg, 1971; Schoenberg &
Christine, 1974, Prior & Waterhouse, 1981b) involving
mainly breast, corpus uteri and colon and were tentatively
attributed to common hormonal factors.
Table Vn Ovarian cancer: subsequent cancers of con-
nective tissue, nervous system, urinary system, lung and
large bowel by treatment group and interval from first
primary
Interval (years)
1-9 10+
Treatment
group
Urinary system
RT/CT
OT
Total
Connective tissue
RT/CT
OT
Total
Nervous system
Any RT
OT+CT
Total
Lung
Any RT
OT+CT
Total
Colon/rectum
RT/CT
OT
Total
0 E OIE 0
4
0
4
2
1
3
3
1
4
6
7
8
14
22
1.5
1.5
3.0
0.2
0.2
0.4
0.6
0.7
1.3
2.3
3.3
5.6
6.1
6.6
12.7
2.7
1.3
l0.0a
5.0
7.5b
s.oa
1.4
3.la
0.4
1.8
1.3
1.3
2. 1b
1.7a
4
0
1
1
2
6
11
33
6
9
E OIE
0.8
0.9
1.7
0.1
0.1
0.2
0.2
0.3
0.5
1.3
1.6
2.9
2.9
3.9
6.8
1.3
4.4a
2.9a
10.0
5.0
5.0
3.3
4.0
3.8a
3.8b
3.8c
1.0
1.5
1.3
ap<o s5; bp<0.01; cp<0.f1.l
Later studies separated irradiated from non-irradiated
patients. Increased risks associated with radiotherapy were
found for endometrium and bladder (Reimer et al., 1978)
and for colon (Curtis et al., 1985). In patients treated
between 1970 and 1975 (Reimer et al., 1978) a nine-fold risk
of leukaemia was found in association with chemotherapy,
but not radiotherapy, but in the Connecticut Registry mater-
ial, which included registrations up to 1982, the risk of acute
non-lymphatic leukaemia was significantly increased in bothSUBSEQUENT PRIMARY CANCERS 457
the irradiated and non-irradiated groups, although chemo-
therapy may have been used in both (Curtis et al., 1985).
The overall relative risk of subsequent primaries in our series
of 1.5 was marginally higher than the 1.2 of the recent
international study (Kaldor et al., 1987), probably because
the latter analysis was restricted to the first subsequent
primary only. The difference in relative risks was not,
however, significant (X2=2.63). In general the results from
our series are consistent with previous studies with regard to
the range of associations but a relationship with a specific
treatment is not supported in every instance.
Acute and non-lymphocytic leukaemia
The emergence of A+NLL as a high risk site in later
calendar years supports the growing evidence of a leukaemo-
genic effect of chemotherapy, in particular of the alkylating
drugs. In our series a significant excess of A+NLL was
found only in those treated by chemotherapy. The small but
not significant increase in those treated by radiotherapy is
consistent with that found for cervical cancer patients in the
International Study of Cervix Cancer (Day & Boice, 1983)
who had also received pelvic irradiation, particularly external
irradiation (Boice et al., 1987). No excess of leukaemia was
found in the Birmingham series of cervical cancer patients,
which formed part of the International Study, because,
possibly, a higher proportion were treated solely by intra-
cavitary radium, external irradiation being reserved for
patients with disseminated disease (Prior & Brown, 1983).
The lack of effect in the RT+CT group might weigh
against a treatment effect for the individual modalities.
However, only a small group (609 patients) received both
treatments of whom only 16.3% survived 5 years. It seems
likely, therefore, that in this group the treatments were
given, either together or at an interval, to palliate progressive
disease and that doses would have been relatively lower and
of shorter duration.
In a recent review of 83 reported cases of A+NLL
following ovarian cancer (De Gramont et al., 1986), all but
two patients had received at least one alkylating drug;
melphalan (40%), cyclophosphamide (18%), thiotepa (16%),
chlorambucil (16%), 5-fluorouracil (16%) and treosulphan
(14.5%), the mean duration of chemotherapy being 31.4
months (range 2-90 months) and the mean interval between
cancers being 57.3 months (range 15 143 months). The five
patients in our series who developed A+NLL had received
cyclophosphamide, trenimon and thiotepa. The average
duration of therapy (48 months) and the mean interval
between ovarian cancer and A+NLL (60 months) were
consistent with the above report. Our results are also
consistent with the general finding in the collaborative
registry study (Kaldor et al., 1987) where the overall risk of
A+NLL was 3.4 (after exclusion of our results) compared
with 7.0 (95% CI 3.2-13.2) in our series and the risk was
found to remain high beyond 10 years of follow-up. Both
the EMR of 2.4 per 103 PYR and the cumulative risk of
3.1% of A+NLL in our series of ovarian cancer patients
were marginally higher than those found for Hodgkin's
disease treated by chemotherapy, 1.0 per 103 PYR and 1.7%
respectively (Prior & Pope, 1988). This difference may arise
because, although treatment for Hodgkin's disease is aggress-
ive, the cyclical nature of the dosage may allow some bone
marrow recovery whereas, in general, chemotherapy for
ovarian cancer was continuous and of long duration. The
two cases of the A+NLL found in the OT group, although
not constituting a significant excess, gave a RR of 2.5.
However, it was found that the patient developing A+NLL
within 2 years of the ovarian cancer had previously been
treated by splenectomy for aplastic anaemia and may, there-
fore, have been predisposed to leukaemia (Van Leeuwen et
al., 1987). The second case developed acute monocytic
leukaemia some 22 years after the ovarian cancer when the
expected number was approximately 1.0, and may, therefore,
represent a chance effect.
Breast
Pelvic irradiation might expose the breast to a small dose of
around 30rad (Stovall, 1983) and be a potential source of
increased risk, whereas ablation of the ovaries might
decrease the risk. In a similar study of cervical cancer such a
reduction was shown mainly for women irradiated before the
age of 40 years, although the risk was reduced across all age-
groups (Day & Boice, 1983). In a case-control study of this
same material, however, no dose relationship could be
demonstrated for breast (Boice et al., 1987). Although a
general consensus supports a hormonal relationship between
cancers of the breast and ovary, the mechanism is not clear.
The fact that the majority of patients in our series did not
have a functioning ovary suggests that the increased risk of
breast cancer was not directly due to the action of ovarian
hormones but to other common aetiological factors. The
overall relative risk in our series (1.7, 95% CI 1.3-2.2) was
marginally higher than that of 1.4 found in the international
study (Kaldor et al., 1987). This difference is probably due
to the inclusion of third and later primaries in the analysis.
Urinary system
An increased risk of bladder cancer has been reported after
pelvic irradiation for benign disease (Wagoner, 1984) and for
cancer of the cervix (Day & Boice, 1983). Data from the
atomic bomb survivors (Preston, 1987) and from cervical
cancer patients surviving 10 or more years (Boice et al.,
1987) are suggestive of a radiation dose response for bladder
cancer. There is also evidence that alkylating agents, in
particular cyclophosphamide, are associated with bladder
cancer (Kinlen, 1981; IARC, 1981). Cyclophosphamide was
a commonly used drug in our series but an RT/CT effect
was not supported by our data, the excess being mainly in
the OT group. There were, however, relatively few long-term
survivors in the RT/CT group.
Connective tissue
Although the excess of soft tissue sarcomas occurred mainly
in the RT/CT groups 1-9 years after first treatment, the
results were not conclusive. The one case in the OT group at
10+ years had in fact been treated for breast cancer 27 years
previously but radiotherapy for this condition could not be
confirmed. Similar excesses of connective tissue cancers were
found in the collaborative registry studies of cervical cancer
(Day & Boice, 1983) and of ovarian and testicular cancer
(Kaldor et al., 1987) but, again, no clear distinction with
type of treatment could be made.
Nervous system
Radiation doses to the brain from pelvic irradiation are
likely to be low, probably less than 10 rads (Stovall, 1983). A
marginal exccess of cancers was found in the RT group
(0=4, E=0.8, RR=5.0, P<0.01) the excess risk, again,
occurring mainly in the first nine years of follow-up, but
with a generalised elevation of risk. Five of the cancers
observed occurred in various lobes of the brain and were of
varying histological type including one meningioma; the
sixth cancer was a meningioma of the spinal cord. In the
collaborative registry study a small excess of nervous system
tumours was found in the ovarian cohort (Kaldor et al.,
1987) but a small deficit occurred in the cohort of cervical
cancer patients (Day & Boice, 1983). Deaths from cancers of
the central nervous system were, however, increased in
patients receiving one course of radiotherapy for ankylosing
spondylitis (Darby et al., 1987).
Respiratory system
Although lung contributes to the excess in the RT group and458 P. PRIOR & D.J. POPE
is in excess 10 or more years after treatment, an effect for
RT is not strongly supported. Only moderate excesses of
lung cancer were found in the collaborative registry study
(Kaldor et al., 1987) and in an individual contribution to
this study (Coleman et al., 1987). Although radiation has
been implicated in the development of lung cancer (Smith &
Doll, 1982; Kato & Schull, 1982), no definitive effect for RT
was found after pelvic irradiation for cervical cancer (Day &
Boice, 1983) from which the lung might receive a typical
dose of around 30rads (Stovall, 1983). Two further studies
reported increased risks of lung cancer after ovarian cancer
but, again, no radiation effect could be demonstrated
(Reimer et al., 1978; Curtis et al., 1985). However, our
results for lung and urinary system could be consistent with
a smoking or environmental pollution effect in the series
(Mattison & Thorgeirsson, 1978; Wellington et al., 1979),
with the lower risk in the early years of follow-up reflecting
our policy of cautious registration of lung tumours occurring
soon after a first primary.
Colon and rectum
A relationship between cancers of the ovary and colon has
been reported from many studies of multiple primary cancers
(Schoenberg et al., 1974; Storm & Ewertz, 1985; Curtis et al.,
1985; Lynge et al., 1985; Hoar et al., 1985). The association
is apparent whichever cancer is taken as the index site. A
similar relationship, but to a lesser extent, was found for
ovary and rectum. The association has been variously attri-
buted to 'hormonal' factors, low parity and diet. In the
context of treatment effects it may be difficult to identify a
moderate increase in risk due to radiotherapy against the
general effect of a more than two-fold risk for these sites.
Our results were, again, consistent with those of the inter-
national study.
Effects of methodology and other factors
In general, our results support those of other series showing
an association between cancers of the ovary, breast, corpus
uteri and large bowel which can probably be attributed to
common aetiological factors. Discrepancies in the levels of
risks found in the different series may arise, in part, from
differing approaches to the analysis. For example, in a
previous paper on the association between ovary and breast
(Prior & Waterhouse, 1981a), we used a method of comple-
mentary analysis (Prior & Waterhouse, 1981b) to explore the
joint association, when it was possible to include all coinci-
dental and subsequent diagnoses. In the collaborative
registry study (Kaldor et al., 1987), all coincidental and first
year cancers were excluded from the observed numbers and,
in addition, all patients with previous or coincidental cancers
were excluded from the cohort. The effect of applying the
same rules to our analysis would have been to eliminate 26
cases from the observed numbers, 15 of whom had been
treated by RT. Although this approach may not invalidate
the analysis in the context of treatment effects, it may bias
the estimates for aetiological associations unrelated to treat-
ment: in our series a large proportion of previous and
coincidental cancers and 12 of the 26 third or later primaries
were of the breast, colon, rectum and uterus, which have
been shown in many analyses to be associated with ovary.
Thus an arbitrary exclusion of 4% of the original cohort,
which may represent a high risk sub-group, will lead to an
under-estimation of risk in later years.
The collaborative study used only the first subsequent
cancer in the analysis. In our study we excluded no case
from the cohort on the basis of coincidental cancers but we
did exclude observed and expected numbers for the first year
of follow-up from the analyses. The major difference in our
approach was to retain patients, who developed a second
primary, in the person-years at risk. The argument against
this procedure was that treatment to the second primary
might invalidate any conclusions drawn with respect to the
initial treatment groups. Our contention was that, with
respect to solid tumours, treatment effects in particular from
radiotherapy would become apparent in long-term survivors
and that third and subsequent primaries may well be of
more relevance in this context. If the effects from superficial
irradiation to rodent ulcers can be discounted, the inclusion
of third and subsequent primaries did not alter the allocation
of observed cases to our originally defined treatment groups.
Other factors might, however, affect the accuracy of the
treatment groupings. It was found that if treatment to a
primary, previous to or coincidental with the ovarian cancer,
was taken into account, only 20 patients would need to be
re-classified and the effect, if discernible, would enhance the
risks in the OT and CT groups. Only one observed case was
in doubt: a patient with a third primary of connective tissue
mentioned above.
Incomplete reporting of treatments could also affect the
allocation to treatment groups but it is not possible to
validate the data for this without referring back to hospital
records. Transcription errors of the data might also occur,
but on the basis of a 4% sample we concluded that these
would not have an appreciable effect on the expected
numbers.
Despite some of the uncertainties inherent in routinely
collected Registry data, our analyses have been able to
demonstrate an increased risk of A+NLL in patients receiv-
ing chemotherapy. Whether we have seriously underesti-
mated the risk from radiotherapy can only be resolved by
further follow-up or more detailed case-control studies.
However, the results do suggest that analyses by treatment
group, even in the broad categories used here, enhance the
use of Registry data in exploratory cohort studies.
The Multiple Primary Cancer Study was supported by the Cancer
Research Campaign.
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